Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
BOSTON, MA – April 8, 2025 – Portal Instruments, a leader in innovative drug delivery solutions, will showcase its new device, PRIME Nexus, at the Pre-Filled Syringes and Injectable Drug Devices conference in Boston, April 28-30.
PRIME Nexus is a reusable electro-mechanical autoinjector, leveraging Portal’s PRIME needle-free platform. Compatible with 1.0 mL and 2.25 mL pre-filled syringes, Nexus offers a sustainable solution for a wide range of injectable medications and is currently available for feasibility studies.
Attendees are invited to meet with CCO Steven Kaufman for personalized demonstrations and to discuss the device's capabilities. “We’re thrilled to present PRIME Nexus alongside Gerresheimer at the PFS conference,” stated Kaufman. “The surge in injectable therapies, exemplified by GLP-1 drugs, necessitates a shift towards reusable solutions to mitigate the significant waste generated by single-use devices. PRIME Nexus represents a forward-thinking approach to injector technology.”
For companies traveling to Boston, the Portal team extends an invitation to visit their Cambridge office for a closer look at their technology.
June 30, 2022 - Logan Merrill has taken testosterone injections for 6 years. In this piece, Logan talks about his transition and the process of taking his injections. This blog was written by Logan Merrill for Portal Instruments. All opinions and experiences shared are entirely his own.
Portal Instruments, a leader in patient-centric drug delivery innovation, is pleased to announce the publication of a collaborative study in the journal Bioengineering & Translational Medicine, highlighting the viability of its next-generation, needle-free injector (NFI) fo
September 28, 2021 - Cambridge, MA Portal Instruments, developer of the PRIME needle-free drug delivery platform, announced that a new clinical study demonstrating patient preference for PRIME needle-free injections was published this month in the journal Drug Delivery.
Please fill out the details below and we will get back to you shortly.